{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:01:06Z","timestamp":1794916866831,"version":"4.9.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We retrospectively compared the therapeutic effects of combination therapy with prednisolone (PSL) and oral tacrolimus (TAC) or azathioprine (AZA) on progressive interstitial pneumonia with systemic sclerosis (SSc-PIP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The effects of PSL (0.2\u20130.5\u2009mg\/kg\/day) and TAC (3\u2009mg\/day) or AZA (1\u20132\u2009mg\/kg\/day) therapies (n\u2009=\u200918) were evaluated for short (12\u00a0months) and long (36\u00a0months or more) periods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the short period, IP improved in 6 and 5 patients and was stable in 12 and 13 patients in the TAC and AZA groups, respectively. In the long period, 11 patients were followed up in the TAC group and 12 in the AZA group. IP improved in 4 and 2 patients and was stable in seven and nine in the TAC and AZA groups, respectively. The rates of evolution of total fibrosis score, and those corrected by disease duration for the long period, in the TAC group were significantly lower than those in the AZA group (p\u2009=\u2009.017 and .025, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The inhibitory effect of PSL and TAC combination therapy on the progression of fibrosis in SSc-PIP may be superior to that of PSL and AZA in the long period.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1080\/14397595.2021.1918864","type":"journal-article","created":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T07:42:46Z","timestamp":1619336566000},"page":"358-364","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of therapeutic effects of combination therapy with prednisolone and tacrolimus or azathioprine on progressive interstitial pneumonia with systemic sclerosis"],"prefix":"10.1093","volume":"32","author":[{"given":"Takao","family":"Kiboshi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical College, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kotani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical College, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Konma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical College, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiko","family":"Makino","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical College, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical College, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayasu","family":"Suzuka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical College, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical College, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Shiba","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical College, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Hata","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical College, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Shoda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical College, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical College, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"issue":"10103","key":"2022030105024113400_R1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"2022030105024113400_R2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/acr.21583","article-title":"Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis","volume":"64","author":"Steele","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"6","key":"2022030105024113400_R3","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/BOR.0000000000000544","article-title":"Recent progress in systemic sclerosis-interstitial lung disease","volume":"30","author":"Castelino","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"2022030105024113400_R4","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"25","key":"2022030105024113400_R5","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"2022030105024113400_R6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3109\/s10165-010-0403-6","article-title":"Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up","volume":"21","author":"Tochimoto","year":"2011","journal-title":"Mod Rheumatol"},{"issue":"2","key":"2022030105024113400_R7","first-page":"293","article-title":"Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase","volume":"25","author":"Air\u00f2","year":"2007","journal-title":"Clin Exp Rheumatol."},{"issue":"10","key":"2022030105024113400_R8","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2022030105024113400_R9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.amjmed.2010.12.009","article-title":"Adverse events during the Scleroderma Lung Study","volume":"124","author":"Furst","year":"2011","journal-title":"Am J Med"},{"issue":"9","key":"2022030105024113400_R10","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"7","key":"2022030105024113400_R11","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of Scleroderma Lung Studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2022030105024113400_R12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022030105024113400_R13","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2165\/00063030-199708060-00005","article-title":"Optimisation of azathioprine immunosuppression after organ transplantation by pharmacological measurements","volume":"8","author":"Bergan","year":"1997","journal-title":"BioDrugs."},{"key":"2022030105024113400_R14","first-page":"898","article-title":"Symposium on immunosuppressive drugs. Biochemistry and pharmacology of purine analogues","volume":"26","author":"Elion","year":"1967","journal-title":"Fed Proc."},{"issue":"2","key":"2022030105024113400_R15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","article-title":"A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis","volume":"25","author":"Nadashkevich","year":"2006","journal-title":"Clin Rheumatol"},{"issue":"7","key":"2022030105024113400_R16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2174\/0929867003374723","article-title":"FK506, an immunosuppressant targeting calcineurin function","volume":"7","author":"Dumont","year":"2000","journal-title":"Curr Med Chem"},{"issue":"6","key":"2022030105024113400_R17","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/14397595.2018.1441658","article-title":"Efficacy and safety of combination therapy with prednisolone and oral tacrolimus for progressive interstitial pneumonia with systemic sclerosis: a retrospective study","volume":"28","author":"Konma","year":"2018","journal-title":"Mod Rheumatol"},{"issue":"11","key":"2022030105024113400_R18","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2022030105024113400_R19","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"issue":"150","key":"2022030105024113400_R20","doi-asserted-by":"crossref","first-page":"180076","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur Respir Rev"},{"issue":"4749","key":"2022030105024113400_R21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/bmj.1.4749.65","article-title":"A simple standard exercise test and its use for measuring exertion dyspnoea","volume":"1","author":"Hugh\u2013Jones","year":"1952","journal-title":"Br Med J"},{"issue":"12","key":"2022030105024113400_R22","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00296-014-3026-y","article-title":"Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study","volume":"34","author":"Poormoghim","year":"2014","journal-title":"Rheumatol Int"},{"issue":"4","key":"2022030105024113400_R23","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s10067-004-0906-7","article-title":"Experience with azathioprine in systemic sclerosis associated with interstitial lung disease","volume":"23","author":"Dheda","year":"2004","journal-title":"Clin Rheumatol"},{"issue":"9","key":"2022030105024113400_R24","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1177\/0961203312442259","article-title":"Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial","volume":"21","author":"Chen","year":"2012","journal-title":"Lupus"},{"issue":"1","key":"2022030105024113400_R25","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41598-017-00860-y","article-title":"Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"2022030105024113400_R26","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.transproceed.2009.06.049","article-title":"Evolution of rejection rates and kidney graft survival: a historical analysis","volume":"41","author":"Marc\u00e9n","year":"2009","journal-title":"Transplant Proc"},{"key":"2022030105024113400_R27","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"2022030105024113400_R28","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1002\/art.22927","article-title":"Presence of CD4\u2009+\u2009CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis","volume":"56","author":"Parel","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2022030105024113400_R29","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/1529-0131(199906)42:6<1168::AID-ANR13>3.0.CO;2-L","article-title":"Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis","volume":"42","author":"Atamas","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2022030105024113400_R30","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/ar3486","article-title":"Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease","volume":"13","author":"Truchetet","year":"2011","journal-title":"Arthritis Res Ther"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1080\/14397595.2021.1918864\/41830175\/1918864.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/2\/358\/42644806\/1918864.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/2\/358\/42644806\/1918864.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T05:03:12Z","timestamp":1646110992000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/2\/358\/6471305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,8,31]]},"published-print":{"date-parts":[[2022,2,28]]}},"URL":"https:\/\/doi.org\/10.1080\/14397595.2021.1918864","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,8,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=imor20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=imor20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}